key: cord-0013028-a229w77e
authors: Kim, Jong-Hwa; Kim, Kiyoung; Kim, Wonyong
title: Genipin inhibits rotavirus-induced diarrhea by suppressing viral replication and regulating inflammatory responses
date: 2020-09-28
journal: Sci Rep
DOI: 10.1038/s41598-020-72968-7
sha: 6d39c83f8c82a89c4604f3e5bcdb0bc2df14f6a4
doc_id: 13028
cord_uid: a229w77e

Rotavirus is the leading cause of acute gastroenteritis among young children worldwide. However, agents specifically designed to treat rotavirus infection have not been developed yet. In this study, the anti-rotavirus and anti-inflammatory effects of genipin, a chemical compound found in the fruit of Gardenia jasminoides, were evaluated. Genipin had an antiviral effect against the human rotavirus Wa and SA-11 strains in vitro, and it inhibited two distinct stages of the viral replication cycle: attachment and penetration (early stage) in pre-treatment and assembly and release (late stage) in post-treatment. Additionally, genipin downregulated nitric oxide synthase and pro-inflammatory cytokines in lipopolysaccharide-stimulated RAW264.7 cells and rotavirus-infected Caco-2 cells. Oral administration of genipin before and after viral infection with the murine rotavirus epidemic diarrhea of infant mice strain led to a reduced duration of diarrhea and faecal viral shedding and to decreased destruction of the enteric epithelium. Genipin could have potential as a natural compound with preventive and therapeutic effects against infection and colitis caused by rotavirus.

Effects of NO, PGE 2 , and pro-inflammatory cytokine generation. The inhibitory effects of genipin on accumulated production of LPS-induced NO and PGE 2 were determined in the cell supernatant of macrophage RAW264.7 cells treated with genipin at concentrations of 10, 50, 100, and 150 µM/mL in the presence of 0.1 μg/μL of LPS. Compared with the control of LPS-induced NO, accumulated NO and PGE 2 production in the cell supernatant treated with genipin was significantly inhibited at 50-150 µM/mL (Fig. S2A,B) . In particular, treatment with genipin 50 µM/mL resulted in NO and PGE 2 production rates of 12% and 30%, respectively, relative to the untreated control. The levels of IL-6, IL-10, and IL-1β were significantly inhibited at genipin concentrations of 50-150 µM/mL. With 150 µM/mL of genipin, the IL-6 level was 4.0 pg/mL (compared with untreated control, 16.3 pg/mL) (Fig. S2C ), the IL-10 level was 14.8 pg/mL (compared with untreated control, 84.8 pg/mL) (Fig. S2D) , and the IL-1β level was 10.8 pg/mL (compared with untreated control, 43.9 pg/mL) (Fig. S2E ). In contrast, the TNF-α level was slightly inhibited. At a genipin concentration of 150 µM/mL, the TNF-α level was 18.6 pg/mL (compared with untreated control, 21.0 pg/mL) (Fig. S2F ).

To evaluate the inhibitory effects of genipin against inflammation by rotavirus infection, NO and PGE 2 were measured in virusinfected Caco-2 cell supernatant fluid (Fig. 1) . The Caco-2 cells infected with rotavirus were used as a positive control. NO and PGE 2 production were inhibited at genipin concentrations of 50-150 µM/mL in both pre-and post-treatment, compared with the positive control (Fig. 1A,B) . The level of pro-inflammatory cytokines was significantly inhibited at genipin concentrations of 50-150 µM/mL in both pre-and post-treatment contexts. In detail, at a genipin concentration of 100 µM/mL, the IL-6 level was 22.7 pg/mL in pre-treatment and 16.6 pg/mL in post-treatment (compared with positive control, 67.3 pg/mL) (Fig. 1C ), the IL-10 level was 50.0 pg/mL in pretreatment and 51.0 pg/mL in post-treatment (compared with positive control, 118.0 pg/mL) (Fig. 1D ), the IL-1β level was 3.5 pg/mL in pre-treatment and 2.6 pg/mL in post-treatment (compared with positive control, 36.9 pg/ mL) (Fig. 1E) , and the TNF-α level was 178.6 pg/mL in pre-treatment and 177.9 pg/mL in post-treatment (compared with positive control, 261.5 pg/mL) (Fig. 1F) . At a genipin concentration of 150 µM/mL, the IL-6 level was 22.4 pg/mL in pre-treatment and 22.0 pg/mL in post-treatment (Fig. 1C ), the IL-10 level was 45.8 pg/mL in pre-treatment and 54.5 pg/mL in post-treatment (Fig. 1D ), the IL-1β level was 3.8 pg/mL in pre-treatment and 5.3 pg/mL in post-treatment (Fig. 1E) , and the TNF-α level was 172.1 pg/mL in pre-treatment and 189.5 pg/mL in post-treatment (Fig. 1F ).

Genipin inhibits rotavirus in a dose-dependent manner. The inhibitory effects of genipin against the human rotavirus Wa strain and simian rotavirus SA-11 strain in MA104 cells were determined by a real-time PCR viral titre assay using different strategies. As expected, viral titre was significantly reduced by genipin treatment in a dose-dependent manner. Genipin pre-treatment significantly reduced the Wa strain viral titre (5.02 log of 10 µM, 4.16 log of 50 µM, 3.17 log of 100 µM, and 0.86 log of 150 µM) and SA-11 strain viral titre (5.50 log of 10 µM, 5.22 log of 50 µM, 3.55 log of 100 µM, and 3.18 log of 150 µM), compared with untreated control (7.53 log and 6.23 log, respectively) in MA104 cells ( Fig. 2A) . Post-treatment also significantly reduced Wa strain viral titre (6.14 log of 10 µM, 3.88 log of 50 µM, 2.86 log of 100 µM, and 2.94 log of 150 µM) and SA-11 strain viral titre (5.8 log of 10 µM, 4.53 log of 50 µM, 3.97 log of 100 µM, and 2.88 log of 150 µM), compared with untreated control (8.18 log and 6.23 log, respectively) in MA104 cells (Fig. 2B) .

To assess whether genipin treatment could inhibit rotavirus Wa and SA-11 infectivity in a dose-dependent manner, we used Caco-2 cells for the relevant antiviral assay. Genipin pre-treatment significantly reduced Wa strain viral titre (6.16 log of 10 µM, 6.09 log of 50 µM, 5.97 log of 100 µM, and 5.04 log of 150 µM) and SA-11 strain viral titre (6.11 log of 10 µM, 5.98 log of 50 µM, 5.79 log of 100 µM, and 5.11 log of 150 µM) compared with untreated control (6.41 log and 6.49 log, respectively) in Caco-2 cells (Fig. 2C) . The post-treatment assay also significantly reduced Wa strain viral titre (6.01 log of 10 µM, 5.75 log of 50 µM, 5.74 log of 100 µM, and 5.29 log of 150 µM) and SA-11 strain viral titre (6.06 log of 10 µM, 5.86 log of 50 µM, 5.72 log of 100 µM, and 5.14 log of 150 µM), compared with untreated control (6.41 log and 6.49 log, respectively) in Caco-2 cells (Fig. 2D ).

Inhibitory impact of genipin on rotavirus plaque formation in MA104 cells. Genipin was evaluated for anti-rotavirus activity in a plaque assay (Fig. S3) . The wells pre-treated with genipin showed significantly lower plaque numbers at concentrations of 10, 50, 100, and 150 µM compared with untreated control wells. Genipin inhibits rotavirus in an MOI-dependent manner. MA104 cells were infected with multiplicities of infection (MOIs) of 0.1, 0.5, and 1 (Fig. 3) . In genipin pre-and post-treatment, infectious virus particle production was significantly inhibited at MOIs of 0.1, 0.5, and 1. Genipin pre-treatment significantly reduced viral titre (5.92 log of MOI 0.1, 6.09 log of MOI 0.5, and 6.19 log of MOI 1). Genipin post-treatment also significantly reduced viral titre (5.89 log of MOI 0.1, 5.99 log of MOI 0.5, and 6.12 log of MOI 1), compared with untreated control (6.10 log of MOI 0.1, 6.17 log of MOI 0.5, and 6.32 log of MOI 1).

Effects on the viricidal activity of genipin. The viricidal activity of genipin against the human rotavirus Wa strain was determined via a real-time PCR viral titre assay using MA104 cells (Fig. 4) . The genipin inhibited the Wa strain viral activity (6.17 log of 10 µM, 6.09 log of 50 µM, 6.07 log of 100 µM, and 5.98 log of 150 µM) relative to untreated control (6.32 log). www.nature.com/scientificreports/ Impact of genipin on EDIM-induced diarrhea. The impact of genipin on EDIM-induced diarrhea in neonatal mice was tested at a genipin concentration of 100 µM/mouse. At 20,000 PFU/mouse, the mice pretreated with genipin (0%; p < 0.05) and those post-treated with genipin (0%; p < 0.05) had a significantly lower diarrhea score than the mice in the EDIM group (22.0%) from day 4 after infection ( Fig. 6A ). On days 7-8, there were significant differences between the mice pre-treated and post-treated with genipin. The incidence of diarrhea among pre-treated mice (0%) was significantly lower than that among post-treated mice (50% on day 7 and 67% on day 8). Specifically, none of the mice pre-treated with genipin had diarrhea, compared with 100% of the mice with acute diarrhea and severe dehydration in the EDIM group after infection. The diarrhea score among mice post-treated with genipin (0; p < 0.05) was significantly lower than that among mice in the EDIM group (0.67) on day 4 after infection ( Fig. 6B ). On days 5-6, the diarrhea scores showed significant differences (p < 0.0001) in both the pre-treated (0.50 and 0.23, respectively) and post-treated groups (0 and 0.72, respectively), compared with the EDIM group (2.86 and 2.00, respectively). All groups showed decreased diarrhea scores on day 8. Interestingly, mice post-treated with genipin had a diarrhea score of 0 until day 6, and a score ≤ 1 on days 7-8.

We wanted to confirm whether these approaches also influenced viral load. Total cellular RNA levels isolated from the faeces of neonatal mice pre-treated or post-treated with genipin were analysed by real-time RT-PCR to obtain a number of RNA copies of the EDIM VP6 gene (Fig. 7) . From days 1-4, no significant differences in viral RNA shedding titre were observed in the four groups. On day 7, the viral RNA shedding titre in the EDIM group reached its peak by 6.95 log. In contrast, the viral RNA shedding titres in mice pre-treated (2.83 log; p < 0.0001) or post-treated with genipin (4.38 log; p < 0.0001) were significantly lower than that in the EDIM group. There were statistically significant differences (p < 0.005) between the pre-treated and post-treated groups on days 6-8. www.nature.com/scientificreports/

Rotavirus is still the leading cause of acute gastroenteritis among young children worldwide. Approximately 95% of children experience at least one rotavirus infection by the age of 5 years 30 . Since antibiotic treatment is nonspecific for rotavirus infection, vaccination is the most important strategy recommended by the World Health Organization to protect children against rotavirus-related hospitalization and death 31 . According to a recent study, only 53 countries offer rotavirus vaccines through their national immunization programs 32 . The efficacy of rotavirus vaccines is < 90%, so new preventive and therapeutic strategies need to be developed. Our data showed that rotavirus-infected MA104 cells treated with different concentrations of genipin secreted decreased levels of different inflammatory markers (IL-6, IL-10, IL-1β, and TNF-α); we also observed a genipin effect against the inflammatory responses of LPS-induced macrophage RAW264.7 cells. IL-6, IL-1β, and TNF-α are pro-inflammatory cytokines known as triggers of pathologic pain 33, 34 .

Previous studies have indicated that some natural products and their secondary metabolites, such as pectic polysaccharides (Panax ginseng), epigallocatechin gallate, and theaflavin (green tea) have inhibitory effects against rotavirus 35, 36 . However, these studies showed no inhibitory effects against rotavirus infection in either pre-or post-treatment. In the present study, pre-and post-treatment with genipin was associated with inhibitory effects against the human rotavirus Wa and SA-11 strains in MA104 and Caco-2 cells. Plaque numbers and quantification of viral titre via real-time PCR indicated significant decreases in viral infection associated with www.nature.com/scientificreports/ both pre-and post-treatment with genipin. These results indicate that genipin can be used in the prevention and treatment of rotavirus infection. Moreover, anti-rotavirus activity was dose-dependently and MOI-dependently affected by genipin in both pre-and post-treatment contexts. Genipin also suppressed rotavirus replication at two distinct stages of the viral replication cycle: the rotavirus RNA replication cycle in MA104 cells was significantly inhibited at the early stage in pre-treatment and the late stage in post-treatment. These results are supported by previous studies, which indicated that kuraridin isolated from Sophora flavescens and iridoid glycosides extracted from Fructus Gardeniae have inhibited reovirus and influenza virus by replication cycles in pre-and post-treatment 37, 38 . Additionally, genipin showed viricidal effects against rotavirus. Anti-rotaviral activity (e.g., inhibiting viral replication and viricidal effects) has previously been reported in association with natural products, including against porcine rotavirus (G5P [7] ) and bovine rotavirus (G8P [7] ) 39, 40 .

We also evaluated the inhibitory effects and antiviral activity of genipin against the rotavirus EDIM strain in a murine model. The EDIM group exhibited clinical symptoms of rotavirus infection and high viral shedding, whereas both the pre-treated and post-treated groups exhibited significantly reduced diarrhea incidence and faecal viral shedding. These results are supported by previous in vivo studies, which showed that Glycyrrhiza uralensis and Oryza sativa, and a combination of Sophora flavescens and stevioside, have marked anti-rotavirus effects after induction of rotavirus diarrhea [41] [42] [43] . However, these studies investigated only preventive aspects. Taken together, our results demonstrate that genipin may be applied as a potent medication for preventing and curing rotavirus diarrhea in humans and animals.

In conclusion, genipin showed anti-inflammatory and antiviral activities against rotavirus in vitro and in vivo, which led to significantly reduced diarrhea incidence and suppressed viral shedding, by inhibiting the replication cycle (Fig. 8) . Therefore, our results suggest that further studies are required for in vitro evaluation of various rotavirus types and for preclinical evaluation of genipin to apply new therapeutic strategies against rotavirus infection.

Reagents. Genipin powder (≥ 98% high-performance liquid chromatography purity, G4796) was purchased Cytotoxicity assay. The cytotoxicity of genipin against macrophage RAW264.7, MA104, and Caco-2 cells was determined by MTT assay (Mosmann, 1983) . Briefly, 100 µL of cell suspension containing 5 × 10 4 , 3 × 10 4 , and 3 × 10 4 of RAW264.7, MA104, and Caco-2 cells, respectively, was seeded into each well of a 96-well plate and incubated for 24 h. The cells were then treated with genipin at serial concentrations of 10 to 200 µM/mL. After 24 h of incubation, 5 µL of 5 mg/mL MTT reagent (Sigma-Aldrich) was added to each well and incubated at 37 °C for 4 h. The media were then carefully removed, and 150 µL of DMSO was added. The plates were covered with tinfoil and agitated on an orbital shaker for 15 min. The optical density at 590 nm was measured using a NanoQuant spectrophotometer (Infinite 200; Tecan, Männedorf, Switzerland). After the experiments, cells were harvested by freezing and thawing three times and centrifuged at 3000×g for 5 min, and the supernatant was stored at − 80 °C for quantitative polymerase chain reaction (qPCR) analysis. To validate the possibility of genipin anti-rotavirus activity, the simian strain SA-11 together with the Wa strain were evaluated in MA104 and Caco-2 cells. These experiments were performed using the same methods as above-the genipin antiviral activity methods (1) and (2) . MA104 and Caco-2 cells untreated with genipin were used as a control.

To evaluate the efficacy of genipin against rotavirus infection, rotavirus stock was serially diluted in MOIs of 0.1, 0.5, and 1. MA104 cells were infected with different rotavirus MOIs. The minimal genipin concentration for anti-rotavirus activity was determined to be 100 µM/mL. These experiments were performed using the same methods as above-the genipin antiviral activity methods (1) and (2) .

Genipin kinetics of rotavirus cell release. The rotavirus replication cycle was determined as previously described, with a few modifications [44] [45] [46] [47] . Confluent monolayers of MA104 cells grown in a 96-well plate were washed with alpha-MEM and infected with the human rotavirus Wa strain at an MOI of 0.1. The virus was adsorbed to cells for 1 h at 37 °C. After the adsorption period, the inoculum was removed, and alpha-MEM was added. These experiments were performed using the same genipin antiviral activity methods as above, (1) and (2) . MA104 cells untreated with genipin were used as a control. The infected cell supernatant was collected at different times (0, 1, 3, 6, 9, 12, 24, and 48 h).

Rotavirus quantification using qPCR. Viral (2) In the genipin-treated group for pre-treatment, mice were orally pre-treated with genipin 100 µM/mouse for 5 days before infection with the rotavirus EDIM strain and then with a dose of the EDIM virus mixed with 100 µM/mouse of genipin (EDIM plus genipin) for 5 consecutive days. The mixtures were incubated at room temperature for 1 h in sterile screw-capped vials. For post-treatment, neonatal mice were orally inoculated with a dose of the EDIM virus mixed with 100 µM/mouse of genipin (EDIM plus genipin) for 5 consecutive days. An untreated virus-infected control set was prepared by diluting 10 µL (2 × 10 4 FFU) of virus suspension with 10 µL of PBS (EDIM-infected group), and negative control mice received 20 µL of PBS instead (PBS group). Stool consistency was evaluated on a 5-point scale: severe illness (yellow = 4, brown-yellow = 3, brown = 2, black = 1) and consistency (very liquid = 4, liquid = 3, soft = 2, solid = 1) [49] [50] [51] .

The different categories of diarrhea reflected the amount of water lost during rotavirus infection. Diarrhea severity was reported as a diarrhea score, where level 3 was less severe, and level 4 was most severe. Faeces were collected daily, and EDIM viral shedding was assessed by qPCR analysis. Statistical analysis. Significant differences among the three groups were calculated using two-way analysis of variance with Dunnett's post-test for comparison using GraphPad Prism (v.6.0.1) (GraphPad Software Inc., San Diego, CA, USA). Data are expressed as mean ± standard error of the mean (SEM), and p values < 0.05 were considered significant. www.nature.com/scientificreports/

Rotavirus and severe childhood diarrhea

Global review of the age distribution of rotavirus disease in children aged < 5 years before the introduction of rotavirus vaccination

Rotavirus infection

Gastroenteritis in children: Part II. Prevention and management

Human milk oligosaccharides influence neonatal mucosal and systemic immunity

Conquering rotavirus: from discovery to global vaccine implementation

Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

Options for improving effectiveness of rotavirus vaccines in developing countries

Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

Differentiation of RotaTeq® vaccine strains from wild-type strains using NSP3 gene in reverse transcription polymerase chain reaction assay

Characterization of RotaTeq® vaccine-derived rotaviruses in South Korean infants with rotavirus gastroenteritis

Emergence of human G2P[4] rotaviruses in the post-vaccination era in South Korea: footprints of multiple interspecies re-assortment events

The in vitro antiviral activity of isoprinosine on simian rotavirus (SA-11). Braz

Inhibition of rotaviruses by selected antiviral substances: mechanisms of viral inhibition and in vivo activity

An in vitro study of theaflavins extracted from black tea to neutralize bovine rotavirus and bovine coronavirus infections

Analysis of anti-rotavirus activity of extract from Stevia rebaudiana

Screening of Brazilian medicinal plants for antiviral activity against rotavirus

In vitro anti-rotavirus activity of some medicinal plants used in Brazil against diarrhea

Characterization of in vivo anti-rotavirus activities of saponin extracts from Quillaja saponaria Molina

Genistein inhibits rotavirus replication and upregulates AQP4 expression in rotavirus-infected Caco-2 cells

Potent inhibitor design against H1N1 swine influenza: structure-based and molecular dynamics analysis for M2 inhibitors from traditional Chinese medicine database

Genipin inhibits the inflammatory response of rat brain microglial cells

Genipin, a metabolite derived from the herbal medicine Inchin-ko-to, and suppression of Fas-induced lethal liver apoptosis in mice

Genipin enhances Kaposi's sarcoma-associated herpesvirus genome maintenance

Genipin as a novel chemical activator of EBV lytic cycle

Concise synthesis of 5,6-dihydrovaltrate leading to enhanced Rev-export inhibitory congener

Epidemiology and prevention of vaccine-preventable diseases. Rotavirus

Rotavirus vaccines. WHO position paper

A systematic review of genetic diversity of human rotavirus circulating in South Korea

Cytokines, inflammation, and pain

Pectic polysaccharides from Panax ginseng as the antirotavirus principals in ginseng

Inhibition of rotavirus and enterovirus infections by tea extracts

In vitro anti-reovirus activity of kuraridin isolated from Sophora flavescens against viral replication and hemagglutination

Antiviral activity of iridoid glycosides extracted from Fructus Gardeniae against influenza A virus by PACT-dependent suppression of viral RNA replication

In vitro antiviral activity against rotavirus and astrovirus infection exerted by substances obtained from Achyrocline bogotensis (Kunth) DC.(Compositae)

Antiviral activity of Alpinia katsumadai extracts against rotaviruses

Anti-rotaviral effects of Glycyrrhiza uralensis extract in piglets with rotavirus diarrhea

Anti-rotavirus effects by combination therapy of stevioside and Sophora flavescens extract

Dietary rice bran protects against rotavirus diarrhea and promotes Th1-type immune responses to human rotavirus vaccine in gnotobiotic pigs

Fenner's Veterinary Virology. Chapter 2 Virus Replication 4th edn

Prescott's Microbiology 9th edn

Exopolysaccharide from Lactobacillus plantarum LRCC5310 offers protection against rotavirus-induced diarrhea and regulates inflammatory response

A simple method of estimating fifty per cent endpoint

Rotavirus diarrhea is caused by nonreplicating viral particles

Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT (R192G) or orally with live rhesus rotavirus vaccine candidates

The authors would like to thank Truong Cong Thoi for his contribution of plaque assay. 

The authors declare no competing interests.

Supplementary information is available for this paper at https ://doi.org/10.1038/s4159 8-020-72968 -7.Correspondence and requests for materials should be addressed to W.K.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.